Rheumatoid Arthritis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Rheumatoid Arthritis stocks.

Rheumatoid Arthritis Stocks Recent News

Date Stock Title
Jul 11 REGN Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11 KYMR Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Jul 11 LXRX Private equity firms account for 48% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while individual investors account for 33%
Jul 11 CANF Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
Jul 11 MESO July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects
Jul 10 MESO Insider-Owned ASX Growth Companies To Watch In July 2024
Jul 10 ARGX argenx SE: A Post FDA Approval Assessment
Jul 10 KYMR Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
Jul 9 KYMR Why Kymera Therapeutics Stock Is Soaring Today
Jul 9 KYMR Kymera Therapeutics soars as Sanofi expands phase 2 trials
Jul 9 KYMR Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
Jul 9 KYMR Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
Jul 9 KYMR Biggest stock movers today: BP, INTC, HELE, and more
Jul 9 EBS Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
Jul 9 EBS Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
Jul 9 KYMR Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
Jul 9 LXRX Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
Jul 9 EBS Emergent, J&J resolve dispute over COVID vaccine manufacturing deal
Jul 9 MESO Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
Jul 8 KYMR Kymera announces expansion of KT-474 HS and AD phase 2 studies
Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.While the cause of rheumatoid arthritis is not clear, it is believed to involve a combination of genetic and environmental factors. The underlying mechanism involves the body's immune system attacking the joints. This results in inflammation and thickening of the joint capsule. It also affects the underlying bone and cartilage. The diagnosis is made mostly on the basis of a person's signs and symptoms. X-rays and laboratory testing may support a diagnosis or exclude other diseases with similar symptoms. Other diseases that may present similarly include systemic lupus erythematosus, psoriatic arthritis, and fibromyalgia among others.The goals of treatment are to reduce pain, decrease inflammation, and improve a person's overall functioning. This may be helped by balancing rest and exercise, the use of splints and braces, or the use of assistive devices. Pain medications, steroids, and NSAIDs are frequently used to help with symptoms. Disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, may be used to try to slow the progression of disease. Biological DMARDs may be used when disease does not respond to other treatments. However, they may have a greater rate of adverse effects. Surgery to repair, replace, or fuse joints may help in certain situations. Most alternative medicine treatments are not supported by evidence.RA affects about 24.5 million people as of 2015. This is between 0.5 and 1% of adults in the developed world with 5 and 50 per 100,000 people newly developing the condition each year. Onset is most frequent during middle age and women are affected 2.5 times as frequently as men. In 2013, it resulted in 38,000 deaths up from 28,000 deaths in 1990. The first recognized description of RA was made in 1800 by Dr. Augustin Jacob Landré-Beauvais (1772–1840) of Paris. The term rheumatoid arthritis is based on the Greek for watery and inflamed joints.

Browse All Tags